| Entry |
|
|---|
| Name |
Dasatinib (JAN/INN) |
|---|
| Formula |
C22H26ClN7O2S
|
|---|
| Exact mass |
487.1557
|
|---|
| Mol weight |
488.0055
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 4291 |
| Product (DG00714): | D03658<JP> D06414<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Tyrosine kinase inhibitor |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07045 | Antineoplastics - protein kinase inhibitors |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EA BCR-ABL tyrosine kinase inhibitors
L01EA02 Dasatinib
D03658 Dasatinib (JAN/INN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D03658 Dasatinib (JAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG03161 BCR-ABL inhibitor
DG00714 Dasatinib
D03658 Dasatinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00714 Dasatinib
D03658 Dasatinib
DG02924 UGT substrate
DG00714 Dasatinib
D03658 Dasatinib
Unclassified
DG03306 FMO substrate
DG02950 FMO3 substrate
DG00714 Dasatinib
D03658 Dasatinib
Drug classes [BR:br08332]
Antineoplastic
DG03161 BCR-ABL inhibitor
D03658 Dasatinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
PDGFR family
PDGFRB
D03658 Dasatinib (JAN/INN) <JP>
KIT (CD117)
D03658 Dasatinib (JAN/INN) <JP>
EPH family
EPHA2
D03658 Dasatinib (JAN/INN) <JP>
Non-receptor tyrosine kinases
SRC family
SRC
D03658 Dasatinib (JAN/INN) <JP>
FYN
D03658 Dasatinib (JAN/INN) <JP>
LCK
D03658 Dasatinib (JAN/INN) <JP>
YES1
D03658 Dasatinib (JAN/INN) <JP>
ABL family
BCR-ABL [HSA_VAR:25v1]
D03658 Dasatinib (JAN/INN) <JP>
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D03658
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG03161 BCR-ABL inhibitor
DG00714 Dasatinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00714 Dasatinib
DG02924 UGT substrate
DG00714 Dasatinib
Unclassified
DG03306 FMO substrate
DG02950 FMO3 substrate
DG00714 Dasatinib
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 33
1 C8y C 29.9758 -20.2312
2 N5x N 29.9758 -21.6365
3 C8y C 31.1928 -22.3391
4 N5x N 32.4099 -21.6365
5 C8y C 32.4099 -20.2312
6 C8x C 31.1928 -19.5285
7 N1b N 28.7588 -19.5285
8 N1y N 33.6457 -19.5175
9 C1a C 31.1928 -23.7443
10 C1x C 34.8554 -20.2158
11 C1x C 36.0723 -19.5131
12 N1y N 36.0723 -18.1078
13 C1x C 34.8626 -17.4094
14 C1x C 33.6456 -18.1122
15 C8y C 27.5611 -20.2171
16 S2x S 26.4562 -19.3972
17 C8y C 25.3351 -20.1946
18 C8x C 25.7470 -21.5073
19 N5x N 27.1227 -21.5212
20 C5a C 24.1269 -19.5122
21 N1b N 22.9324 -20.2145
22 O5a O 24.1153 -18.0801
23 C8y C 21.6793 -19.5047
24 C8y C 21.6676 -18.0848
25 C8x C 20.4448 -17.3923
26 C8x C 19.2336 -18.1050
27 C8x C 19.2453 -19.5249
28 C8y C 20.4681 -20.2175
29 X Cl 22.8702 -17.3774
30 C1a C 20.4093 -21.5897
31 C1b C 37.2948 -17.4017
32 C1b C 38.5114 -18.1038
33 O1a O 39.6948 -17.4204
BOND 36
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 1 7 1
8 5 8 1
9 3 9 1
10 8 10 1
11 10 11 1
12 11 12 1
13 12 13 1
14 13 14 1
15 8 14 1
16 7 15 1
17 15 16 1
18 16 17 1
19 17 18 2
20 18 19 1
21 15 19 2
22 17 20 1
23 20 21 1
24 20 22 2
25 21 23 1
26 23 24 2
27 24 25 1
28 25 26 2
29 26 27 1
30 27 28 2
31 23 28 1
32 24 29 1
33 28 30 1
34 12 31 1
35 31 32 1
36 32 33 1
|
|---|
